[1] Etxabe J, Vazquez J A.Morbidity andmortality in Cushing's disease: an epidemicological approach[J]. Clin Endocrinol (Oxf),1994,40(4): 479-484.
[2] 孙博文,冯铭,王宁,等. 库欣病的分子水平研究进展[J].中华医学杂志, 2016,1(96): 234-236.
[3] Amaldi G, Angeli A, Atkinson A B, et a1. Diagnosis and complications of Cushing'S syndrome: a consensus statement[J].J Clin Endo-crinol Metab,2003,88(12):5593-5602.
[4] Newell Price J, Bertagna X, Grossman A B, et a1. Cushing'S syndrome[J]. lancet, 2006, 367(9522): 1605-1617.
[5] 刘潜,王红云,李丹,等. EGFL7单克隆抗体抑制小鼠ACTH垂体腺瘤AtT-20细胞增殖和侵袭的作用研究[J].中国药物警戒, 2018,15(6): 321-324.
[6] Derissen E J, Beijnen J H, Schellens J H.Concise drug review: azacitidine and decitabine[J]. Oncologist, 2013, 18(5): 619-624.
[7] Plimack E R, Kantarjian H M, Issa J P. decitabine and its role in the treatment of hematopoietic malignancies[J]. Leuk Lymphoma, 2007, 48(8):1472-1481.
[8] Ueda K, Hosokawa M, Iwakawa S.Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells[J]. Biol Pharm Bull, 2015, 38(8): 1113-1119.
[9] Li D, Xu C Y, Cui R J, et a1.DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4 1[J].Mol Med Rep, 2015, 12(6): 8201-8208.
[10] 郑淑荣,高华,李丹,等. 橘皮素对泌乳素腺瘤细胞增殖和凋亡的作用及其机制研究[J].中国药物警戒, 2018,15(3):129-131.
[11] 郑淑荣,高华,李丹,等.高内涵技术筛选抑制GH3细胞的天然黄酮类化合物的研究[J].中国药物警戒,2018,15(5):257-259,263.
[12] 范宁娟,项萍,段敏,等.应用流式细胞仪检测细胞凋亡的4种方法的比较[J].安徽农业科学,2014,42(32):11240-11242.
[13] 张爱芳. 盐酸氨溴索对非小细胞肺癌A549细胞Bcl-2和Bax基因表达的影响[J].临床肺科杂志,2018,23(8):1483-1487.
[14] 魏薇,王卫庆.库欣病的分子发病机制[J].国际内分泌代谢杂志,2014,34(3):203-206.
[15] 张绿,王镛斐,叶红英, 等.临床多学科综合治疗团队诊治库欣病[J].中华神经外科杂志,2015,31(6):601-604.
[16] 杨莹. 低剂量地西他滨治疗骨髓增生异常综合征的疗效观察[J].中国民康医学,2017,29(24):18-20. |